Reports of clinical trial protocols of coronavirus disease 2019: a systematic review
Journal Title: TMR Integrative Medicine - Year 2022, Vol 6, Issue 5
Abstract
Background: To examine the outcomes heterogeneity of clinical trial protocols of coronavirus disease 2019 (COVID-19) to prioritize the establishment of a core outcome set. Methods: Databases of the International Committee of Medical Journal Editors – accepted clinical trial registry platforms were searched on February 14, 2020 and May 31, 2020. Randomized controlled trials and non-randomized controlled trials of COVID-19 were considered. Patient condition was classified as common, severe, or critical. Interventions included traditional Chinese medicine and Western medicine. We excluded trials that involved discharged patients, psychological intervention, and complications of COVID-19. The general information and outcomes, outcome measurement instruments, and measurement times were extracted. The results were analyzed by descriptive analysis. Results: In all, 19 registry platforms were searched. A total of 97 protocols were selected from among 160 protocols for the first search. For protocols of traditional Chinese medicine clinical trials, 76 outcomes from 16 outcome domains were reported, and almost half (34/76, 44.74%) of the outcomes were reported only once; the most frequently reported outcome was time taken for severe acute respiratory syndrome coronavirus 2 RNA to become negative. Twenty-seven (27/76, 35.53%) outcomes provided one or more outcome measurement instruments. Ten outcomes provided one or more measurement time frame. For protocols of Western medicine clinical trials, 126 outcomes from 17 outcome domains were reported; almost half (62/126, 49.21%) of the outcomes were reported only once; the most frequently reported outcome was proportion of patients with negative severe acute respiratory syndrome coronavirus 2. Twenty-seven outcomes provided one or more outcome measurement instruments. Forty (40/126, 31.75%) outcomes provided one or more measurement time frame. There were > 40 duplicated outcomes between the clinical trials protocols of traditional Chinese medicine and western medicine protocols. All of them were included in the Delphi survey when developing core outcome set for COVID-19. A total of 1,027 protocols were selected from 2,741 protocols for the second search. Forty-two new outcomes and 47 new outcome measurement instruments were reported. Conclusion: Outcome reporting in clinical trial protocols of COVID-19 is inconsistent. Thus, establishing a core outcome set is necessary for diagnosis and management.
Authors and Affiliations
Rui-Jin Qiu, Xu-Xu Wei, Meng-Zhu Zhao, Chang-Ming Zhong, Chen Zhao, Jia-Yuan Hu, Min Li, Ya Huang, Song-Jie Han, Tian-Mai He, Jing Chen, Hong-Cai Shang
Keywords
Related Articles
- EP ID EP701901
- DOI 10.12032/TMRIM202206005
- Views 68
- Downloads 0
Traditional Chinese medicine in antiviral treatment
The Novel Coronavirus (COVID-19), which broke out in Wuhan, China in December 2019, attracted worldwide attention. With a long incubation period and strong infectiousness, COVID-19 poses a great threat to the life and he...
Excellent response to acupuncture treatment in a case of intractable glossopharyngeal neuralgia due to vascular tortuosity: a case report
Objective: Glossopharyngeal neuralgia is a relatively rare neurological condition arising from abnormal irritation of the ninth cranial nerve. The first line of conventional treatment is pharmaceutical followed by surgic...
Chinese patent medicine for stable angina pectoris: protocol for a systematic review and network meta-analysis
Stable angina pectoris is a common condition that affects a wide group of patients with coronary artery diseases. A number of Chinese patent drugs based on classic herbal formulations are available for angina management....
Effects of Yishenbupi (tonifying-kidney and invigorating-spleen) prescription on the expression of renal fibrosis-associated proteins in unilateral ureteral occlusion rats
Objective: To evaluate the effects and mechanism of the Yishenbupi (tonifying-kidney and invigorating-spleen) prescription on the expression of renal fibrosis-associated vimentin, α-SMA, and fibronectin in unilateral ure...
Participating in health care for total hip replacement patients: an integrative review
In recent years, with the continuous improvement of people's health requirements, the awareness of participating in disease diagnosis and treatment has also been constantly enhanced. Patient’s participation has become a...